+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him

  • ID: 4775272
  • Newsletter
  • 3 pages
  • Datamonitor Healthcare
1 of 1
After a 31-year career at Swiss firm Roche Pharmaceuticals, including a six-year stint as CEO, American Daniel O’Day is moving on to head Gilead Sciences, Inc. taking the top leadership role there as chairman and CEO.

Meanwhile, Roche has tapped William Anderson, CEO at Roche-owned Genentech Inc., to take O’Day’s position at Roche’s helm. Read more about this shuffling of leadership among some of the biggest names in pharma, including reactions by analysts and investors, in this informative article from Scrip.
Note: Product cover images may vary from those shown
2 of 1

Loading
LOADING...

Adroll
adroll